AV Remdesivir

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
Zeile 1: Zeile 1:
 +
{{up|PHA antivirals by mechanism}}
  
 
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]
 
*[https://gab.com/Remnant601/posts/104122987152232660 one hospital on...]

Version vom 18. Januar 2021, 20:13 Uhr

PHA antivirals by mechanism


32223926 2020. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING
32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
32258351 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
32054787 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
32239125 2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2
32358203 ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
32145386 ä. Remdesivir as a possible therapeutic option for the COVID-19
32247927 ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
32321732 2020. Remdesivir in covid-19
32357949 2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers
32350436 2020. Hopes rise for coronavirus drug remdesivir
32483554 ä. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
32281114 2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
32401466 2006. Remdesivir
32456606 2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.
32503874 2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
32458279 2020. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
32396771 2020. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary.
32397906 2020. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.
32439198 2020. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
32513665 2020. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
32418190 2020. Early experience with remdesivir in SARS-CoV-2 pneumonia.
32521159 2020. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
32468196 2020. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
32515337 2020. [Remdesivir til behandling af COVID-19-pneumoni].
32445440 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32516797 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
32572516 2020. Remdesivir bei Patienten mit COVID-19.
32589775 2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.

32537956 2020. Uncertainty about the Efficacy of Remdesivir on COVID-19.


32568620 2020. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach.
32407959 2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
32412709 2020. Compassionate Use of Remdesivir in Covid-19. Reply.
32412708 2020. Compassionate Use of Remdesivir in Covid-19.
32412707 2020. Compassionate Use of Remdesivir in Covid-19.
32412706 2020. Compassionate Use of Remdesivir in Covid-19.
32412705 2020. Compassionate Use of Remdesivir in Covid-19.
32554811 2020. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.
32506110 2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
32459919 2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
32446287 2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.
32492200 2020. Remdesivir and Tocilizumab: Mix or Match.
32423584 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
32423580 2020. Remdesivir for COVID-19: challenges of underpowered studies
32573468 2020. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.

32563812 2020. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
32428865 2020. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.


32607555 2020. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
32568289 2020. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
32595613 2020. Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition.
32520466 2020. Remdesivir et Covid-19: resultats negatifs mais methode de recherche (enfin) appropriee !
32574236 2020. Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
32579980 2020. Validity of the UK Early Access to Medicines Scheme Criteria for Remdesivir use in patients with COVID-19 disease.
32562915 2020. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
32594120 2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis